[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edgewise Therapeutics insider activity: Behrad Derakhshan, Chief Business Officer, had RSUs vest and executed related transactions on 08/12/2025. 5,781 restricted stock units vested and were treated as acquired at $0.00. To satisfy tax withholding on those vested RSUs, 2,491 shares were sold in multiple transactions at an average price of $13.3924 (range $13.36–$13.49). Following the transactions the reporting person beneficially owned 23,645 shares of common stock directly. The filing also reports 30,000 newly granted RSUs (vesting beginning 08/12/2026) and a stock option to purchase 180,000 shares at an exercise price of $13.39 (vesting 1/48th monthly beginning 09/12/2025). The newly vested and granted awards are subject to standard service-based vesting schedules.

Positive

• Clear disclosure of vesting, sell-to-cover mechanics and price range ($13.36–$13.49)
• New equity awards (30,000 RSUs and option for 180,000 shares) align executive incentives with shareholders

Negative

• Sell-to-cover resulted in disposition of 2,491 shares, reducing direct holdings
• No forward-looking details on dilution impact or total outstanding share count to contextualize award size

Insights

Securities Analyst

TL;DR: Officer received standard compensation awards; a sell-to-cover satisfied tax withholding—no discretionary large sale reported.

The Form 4 shows routine equity compensation activity for a named officer. 5,781 RSUs vested and a sell-to-cover of 2,491 shares satisfied tax obligations at an average price of $13.3924. The officer also received 30,000 RSUs (vesting from 08/12/2026) and an option for 180,000 shares at $13.39 with monthly vesting starting 09/12/2025. These movements align with corporate compensation practices and do not by themselves indicate material changes in ownership or control.

Corporate Governance Expert

TL;DR: Issuer documented routine grants and vesting; disclosure is clear about sell-to-cover and vesting schedules.

The filing discloses the nature and timing of each award, including that the sale of 2,491 shares was a non-discretionary sell-to-cover to meet statutory tax withholding. Grant terms are explicit: one RSU tranche vested on 08/12/2025, another RSU grant vests beginning 08/12/2026, and an option grant vests monthly starting 09/12/2025. From a governance perspective the disclosure meets Section 16 requirements and identifies the reporting relationship (Officer/Chief Business Officer).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Derakhshan Behrad

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		5,781	A	$0.00	26,136	D
Common Stock	08/12/2025		S		2,491(1)	D	$13.3924(2)	23,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	08/12/2025		M			5,781	(3)	08/12/2034	Common Stock	5,781	$0.00	17,344	D
Restricted Stock Units	$0.00	08/12/2025		A		30,000		(4)	08/12/2035	Common Stock	30,000	$0.00	30,000	D
Stock Option (Right to Buy)	$13.39	08/12/2025		A		180,000		(5)	08/12/2035	Common Stock	180,000	$0.00	180,000	D

Explanation of Responses:

1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

4. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

5. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R Moore Attorney-in-Fact for Behrad Derakhshan	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions by Behrad Derakhshan are reported on EWTX Form 4?

The Form 4 reports 5,781 vested RSUs, a sell-to-cover disposition of 2,491 shares at an average of $13.3924, a grant of 30,000 RSUs, and a stock option for 180,000 shares at $13.39.

Why were 2,491 shares sold in this filing for EWTX?

The sale of 2,491 shares was a sell-to-cover transaction to satisfy statutory tax withholding obligations on vested RSUs, not a discretionary sale.

When do the newly granted RSUs and option for EWTX vest?

The 5,781 RSUs vested on 08/12/2025. The 30,000 RSUs vest in four equal annual installments beginning 08/12/2026. The option for 180,000 shares vests 1/48th monthly beginning 09/12/2025 through its term.

What is the exercise price of the option reported for EWTX?

The reported stock option has an exercise price of $13.39 per share.

How many shares did the reporting person beneficially own after the transactions?

The Form 4 reports the reporting person beneficially owned 23,645 shares of common stock directly following the reported transactions.